Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
53 hedge funds and large institutions have $47.5M invested in Dicerna Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 15 closing their positions.
4% less funds holding
Funds holding: 55 → 53 (-2)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
22% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 18
40% less capital invested
Capital invested by funds: $79.7M → $47.5M (-$32.2M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
+$901K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$614K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$250K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$233K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$222K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.74M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.38M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.12M |
| 4 |
OPPM
Opus Point Partners Management
New York
|
-$579K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$576K |
DRNA Hedge Fund Activity: Q2 2016 in Review
53 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q2 2016, worth a combined $47.5M — down 40% from $79.7M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of DRNA and 13 opened new positions — a net loss of 2 holders — while 18 trimmed existing stakes and 14 added.
The largest buyer was Tiverton Asset Management, adding an estimated $901K. The largest seller was Wellington Management Group, cutting an estimated $5.74M.
- 53 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q2 2016, down from 55 in Q1 2016.
- Funds reported $47.5M of Dicerna Pharmaceuticals, Inc. stock for Q2 2016, down 40% quarter-over-quarter.
- 13 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q2 2016 and 15 closed out, a net change of -2 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q2 2016 was Tiverton Asset Management, an estimated $901K added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q2 2016 was Wellington Management Group, an estimated $5.74M sold.
Based on aggregated 13F filings for Q2 2016.